0000874015-19-000057.txt : 20190405
0000874015-19-000057.hdr.sgml : 20190405
20190405192914
ACCESSION NUMBER: 0000874015-19-000057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190403
FILED AS OF DATE: 20190405
DATE AS OF CHANGE: 20190405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'NEIL PATRICK R.
CENTRAL INDEX KEY: 0001564926
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 19736200
MAIL ADDRESS:
STREET 1: C/O ISIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-04-03
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001564926
O'NEIL PATRICK R.
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD
CA
92010
0
1
0
0
SVP Legal & General Counsel
Common Stock
2019-04-03
2019-04-03
4
M
0
7654
61.68
A
27327
D
Common Stock
2019-04-03
2019-04-03
4
S
0
7654
84.83
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
15492
61.68
A
35165
D
Common Stock
2019-04-04
2019-04-04
4
S
0
15492
84.75
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
4873
61.68
A
24546
D
Common Stock
2019-04-04
2019-04-04
4
S
0
4873
82.19
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
2657
61.57
A
22330
D
Common Stock
2019-04-04
2019-04-04
4
S
0
2657
82.03
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
2000
47.34
A
21673
D
Common Stock
2019-04-04
2019-04-04
4
S
0
2000
84.20
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
3600
47.34
A
23273
D
Common Stock
2019-04-04
2019-04-04
4
S
0
3600
82.10
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
M
0
8000
49.25
A
27673
D
Common Stock
2019-04-04
2019-04-04
4
S
0
8000
84.29
D
19673
D
Common Stock
2019-04-04
2019-04-04
4
S
0
1122
82.01
D
18551
D
Common Stock
2019-04-04
2019-04-04
4
S
0
1878
84.25
D
16673
D
Common Stock
2019-04-05
2019-04-05
4
M
0
2252
61.68
A
18925
D
Common Stock
2019-04-05
2019-04-05
4
S
0
2252
84.75
D
16673
D
Employee Stock Option (right to buy)
61.68
2019-04-03
2019-04-03
4
M
0
7654
0
A
2019-01-04
2023-01-03
Common Stock
7654
30586
D
Employee Stock Option (right to buy)
61.68
2019-04-04
2019-04-04
4
M
0
20365
0
A
2019-01-04
2023-01-03
Common Stock
20365
10221
D
Employee Stock Option (right to buy)
61.57
2019-04-04
2019-04-04
4
M
0
2657
0
A
2019-01-02
2022-01-01
Common Stock
2657
0
D
Employee Stock Option (right to buy)
47.34
2019-04-04
2019-04-04
4
M
0
5600
0
A
2019-01-03
2024-01-02
Common Stock
5600
20825
D
Employee Stock Option (right to buy)
49.25
2019-04-04
2019-04-04
4
M
0
8000
0
A
2019-01-02
2025-01-01
Common Stock
8000
46638
D
Employee Stock Option (right to buy)
61.68
2019-04-05
2019-04-05
4
M
0
2252
0
A
2019-01-04
2023-01-03
Common Stock
2252
7969
D
Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.025, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.05, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.20 to $84.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) on this Form 4.
The sale was made pursuant to shares owned.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.02, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) on this Form 4.
Patrick R. O'Neil
2019-04-05